PHOSPHOTENSIN TUMOUR SUPPRESSOR GENE (PTEN) EXPRESSION PATTERNS IN ENDOMETRIAL HYPERPLASIAS AND ENDOMETRIOID CARCINOMA

Sithara S1, Sheela Varghese2, Sankar S3

1Resident, Department of Pathology, Government Medical College, Kottayam, Kerala, India.
2Additional Professor, Department of Pathology, Government Medical College, Kottayam, Kerala, India.
3Professor and HOD, Department of Pathology, Government Medical College, Kottayam, Kerala, India.

ABSTRACT

BACKGROUND
Endometrioid Endometrial Carcinoma (EECA) has been postulated to develop from premalignant lesions like endometrial hyperplasia without atypia, to endometrial hyperplasia with atypia. Various studies have shown PTEN tumour suppressor gene mutation in endometrial carcinoma and its precursors. Thus, immunohistochemical expression of PTEN may provide a valuable insight into the category of hyperplasia which can be most definitely classified as “premalignant”. This study evaluated PTEN expression in endometrial hyperplasia with and without atypia and endometrioid carcinoma.

MATERIALS AND METHODS
The present study evaluated PTEN expression in endometrial hyperplasia with and without atypia and endometrioid carcinoma in endometrial curettage and hysterectomy specimens received in Government Medical College, Kottayam from 18/4/2017- 9/9/18.

RESULTS
The mean age of study population was 56.98±10.67 years. PTEN is strongly immunoreactive in all cases of proliferative and secretory phase. There was 100% positivity or 0% negativity in endometrial hyperplasia without atypia. In 37% cases of endometrial hyperplasia with atypia and 61% cases of endometrioid carcinoma, there was complete loss of PTEN expression.

CONCLUSION
Loss of PTEN expression is partially associated with endometrioid endometrial cancers via a premalignant phase.

KEY WORDS
PTEN (Phosphotensin Tumour Suppressor Gene); Endometrial Hyperplasia; Endometrioid Carcinoma; Immunohistochemistry.


It is extensively researched upon as an informative marker for delimiting neoplastic and pre-neoplastic glands from normal background endometrial glands. The utility of PTEN expression as a marker for atypical hyperplasias progressing to malignancy could perhaps help provide valuable insight into the category of hyperplasias which can be most definitely classified as “premalignant”. This study evaluates PTEN expression in endometrial hyperplasia and endometrioid carcinoma.

MATERIALS AND METHODS
Type of Study
Descriptive study.

Period of Study
18 months (18/4/2017- 9/9/18)

Study Setting
Department of Pathology, Government Medical College, Kottayam.

Study Population
Endometrial biopsies and hysterectomy specimens with histopathological features diagnostic of endometrial hyperplasia and endometrioid endometrial carcinoma received in the Department of Pathology, Government medical college, Kottayam.
Sample Size
Calculated by the formula \( z^2pq/d^2 \)
Where \( p= \) prevalence/proportion of cases with PTEN loss in the parent study
\( q= 100-p \)
\( d= \) precision (Allowable error)
Here, \( p= 60 \) (From study conducted by Patou Tantbirojn et al.) \(^6\)
\( q= 40 \)
\( d=20\% \) of \( p \), \( z= 1.96 \) at 95\% confidence interval.

Study Procedure
- All specimens are received in formalin. These are processed, paraffin embedded in total. Thin (5 Micrometer) sections were taken and stained by haematoxylin and eosin and IHC study for PTEN was done by Standard Operating Procedure. PTEN intensity and scoring was done according to Soheila Sarmadi et al.\(^7\) and Tantbirojn\(^6\) et al.
- According to majority of studies, immunoreactivity was regarded as positive when brown staining was localized in the nuclei or cytoplasm of normal endometrial gland cell or tumour cell. According to Kapucuoglu et al.\(^15\) and Sarmadi et al.\(^7\) the immunoreactivity was graded semi quantitatively by considering the percentage and intensity of staining on the whole section. Staining of cells was scored as negative if < 10\%, + 1 if 10\%-50\% and +2 if >50\% of slide's area was stained positive. The intensity of PTEN staining was scored from 0 = absent, +1 = light brown, +2 = brown to dark brown in the nucleus or cytoplasm of glandular cells for each specimen. \(^6, 7, 14, 15\)

Data Management and Analysis
The data entered in Microsoft excel was statistically analysed using SPSS 24.

Mean, Frequency and Proportion For
1. Age.
2. Histopathology of endometrial lesions studied.
3. PTEN scoring and intensity in various endometrial lesions.
4. Relation between PTEN scoring and intensity with endometrial hyperplasias with and without atypia and endometrioid carcinoma using chi square test (p value).

RESULTS
7 specimens of endometrial hyperplasia without atypia, 8 specimens of endometrial hyperplasia with atypia and 49 specimens of endometrioid carcinoma were studied.

The mean ages of patients with endometrial hyperplasias without and with atypia and endometrioid carcinomas were 54.43 ± 5.99 years, 54.75 ± 17.91 years and 58.02 ± 9.48 years respectively.
- PTEN was strongly immunoreactive in all cases of proliferative and secretory phase in the current study.
- There was 100\% positivity or 0\% negativity in endometrial hyperplasia without atypia.
- There was complete PTEN loss (Negative immunoreactivity) in 37\% cases of endometrioid carcinoma.
- PTEN immunoreactivity between the different groups of endometrial hyperplasias and endometrioid carcinoma was statistically significant (p<0.001).
- Difference in immunoreactivity between endometrial hyperplasia with atypia and endometrioid carcinoma was not statistically significant.

Gross and Microscopy
DISCUSSION

Endometrial cancer is common in western women with very high rates; but in India, the incidence rates are as low as 2.8 per 100,000 (Mumbai). Hence the studies on endometrial cancer in India are limited. The term "endometrial neoplasia" is a spectrum of morphologic alterations which range from endometrial hyperplasia to endometrial carcinoma.\(^\text{19}\)

PTEN, a tumour-suppressor gene, mutates in 30-50% of endometrioid carcinomas, a rate that is among the highest of any type of tumour analysed to date. It is also found to be mutated in about 13-55% of endometrial hyperplasias.\(^\text{10}\) Moreover, PTEN mutation was seen favourable endometrial carcinoma with a favourable survival.\(^\text{11}\)

This study evaluated the differential expression of PTEN in endometrial hyperplasia and endometrioid carcinoma. This study was done on 7 cases of endometrial hyperplasia without atypia, 8 cases of endometrial hyperplasia with atypia and 49 cases of endometrioid carcinoma. Positive control taken was that of proliferative and secretory endometrium.

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Endometrial Hyperplasia without Atypia</th>
<th>Endometrial Hyperplasia with Atypia</th>
<th>Endometrioid Carcinoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soheila Sarmadi et al.</td>
<td>2009</td>
<td>0%</td>
<td>25%</td>
<td>52%</td>
</tr>
<tr>
<td>Shanmugapriya et al.</td>
<td>2017</td>
<td>11%</td>
<td>50%</td>
<td>70%</td>
</tr>
<tr>
<td>Tantbirojn et al.</td>
<td>2008</td>
<td>24%</td>
<td>60%</td>
<td>60%</td>
</tr>
<tr>
<td>Present Study</td>
<td>2018</td>
<td>0%</td>
<td>37%</td>
<td>61%</td>
</tr>
</tbody>
</table>

PTEN is strongly immunoreactive in all cases of proliferative and secretory phase in the current study. These findings agreed with Soheila Sarmadi et al (2009), in which PTEN immunoreactivity was noted in all proliferative endometrium (29/29, 100%). PTEN expression was significantly higher in proliferative and secretory endometrium than in endometrial hyperplasia with atypia and endometrioid carcinoma.

In endometrial hyperplasia, loss of PTEN expression is found to be 30–63%\(^\text{12,13,14}\) Mutter et al detected loss of PTEN expression in 55% and 63% in endometrial intrapithelial neoplasias in two different studies.\(^\text{13}\)

The current study showed 100% positivity or 0% negativity in endometrial hyperplasia without atypia which is similar to the study by Soheila Sarmadi et al (2009). Studies conducted by Shanmugapriya et al (2017) and Tantbirojn et al (2008) gave comparable findings, i.e., only 11% and 24% cases of endometrial hyperplasia without atypia were negative for PTEN expression.

Our study showed complete PTEN loss or negative immunoreactivity in 37% cases of endometrial hyperplasia with atypia, which is almost comparable to PTEN loss in studies conducted by Soheila Sarmadi et al and Shanmugapriya et al; which were 25% and 50% respectively. Study conducted by Tantbirojn et al showed PTEN negativity in a greater proportion of about 60% cases. Kapucuoglu et al. found complete loss of PTEN in 20% of atypical complex samples.\(^\text{15}\)

The present study showed PTEN negative immunoreactivity in 61% cases of endometrioid carcinoma which is similar to the findings of Tantbirojn et al (60%) and comparable to the findings of Soheila Sarmadi et al (52%).
and Shahmugapriya et al. (70%). Orbo et al reported loss of PTEN protein expression in 55% of specimens in patients who developed subsequent endometrioid endometrial carcinoma.16

Latta E et al (2002) found mutations of the PTEN tumour suppressor gene are present in histologically normal-appearing endometrium exposed to oestrogen, 16-55% of endometrial precancers and 26-80% of EECs.17

There was significant difference in PTEN immunoreactivity between different endometrial hyperplasia and endometrioid carcinoma. (p>0.001). But, there was no significant difference in immunoreactivity between endometrial hyperplasia with atypia and endometrioid carcinoma.

**CONCLUSION**

PTEN expression in endometrioid carcinoma and its precursors was as follows-

- PTEN showed a positive expression in 100% cases of endometrial hyperplasia without atypia.
- Endometrial hyperplasia with atypia showed complete loss of PTEN or negative immunoreactivity in 37% cases.
- PTEN showed negative immunoreactivity in 61% cases of endometrioid carcinoma.

Thus, from our study, diminished PTEN expression was associated with malignant endometrium with statistically significant difference in PTEN immunoreactivity between normal endometrium, hyperplasias and carcinoma. (p>0.001)

Our data suggested that loss of PTEN expression is partially associated with the endometrioid carcinomas via a premalignant phase.

**ACKNOWLEDGEMENTS**

I express my heartfelt thanks and gratitude to Dr. Sankar S, Head of the Department, Department of Pathology, Government Medical College, Kottayam and my guide Dr. Sheela Varghese for their support and help. I am thankful to all my teachers in the Department of Pathology as well as fellow post graduate students and my friends for their wholehearted co-operation and encouragement.

**REFERENCES**